[HTML][HTML] Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN (a) reduction-DOSE finding study (OCEAN (a)-DOSE)
ML O'Donoghue, JAG López, B Knusel, B Gencer… - American Heart …, 2022 - Elsevier
Background Data support lipoprotein (a)(Lp [Lp (a)]) being a risk factor for atherosclerotic
cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA molecule that …
cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA molecule that …
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN (a) reduction-DOSE finding study (OCEAN (a)-DOSE)
ML O'Donoghue, JAG López, B Knusel, B Gencer… - 2022 - pubmed.ncbi.nlm.nih.gov
Background Data support lipoprotein (a)(Lp [Lp (a)]) being a risk factor for atherosclerotic
cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA molecule that …
cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA molecule that …
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN (a) reduction-DOSE finding study (OCEAN (a)-DOSE).
ML O'Donoghue, GL JA, B Knusel, B Gencer… - American Heart …, 2022 - europepmc.org
Background Data support lipoprotein (a)(Lp [Lp (a)]) being a risk factor for atherosclerotic
cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA molecule that …
cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA molecule that …
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN (a) reduction-DOSE finding study (OCEAN (a)-DOSE).
ML O'Donoghue, JA G López, B Knusel… - American Heart …, 2022 - boris.unibe.ch
BACKGROUND Data support lipoprotein (a)(Lp [Lp (a)]) being a risk factor for
atherosclerotic cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA …
atherosclerotic cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA …
[PDF][PDF] Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN (a) reduction-DOSE finding study (OCEAN (a)-DOSE)
ML O'Donoghue, JAG López, B Knusel… - American Heart …, 2022 - scholar.archive.org
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a)
reduction-DOSE finding study (OC Page 1 Trial Designs Study design and rationale for the …
reduction-DOSE finding study (OC Page 1 Trial Designs Study design and rationale for the …
[引用][C] Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN (a) reduction-DOSE finding study (OCEAN (a)-DOSE)
ML O'Donoghue, JAG López, B Knusel, B Gencer… - American Heart …, 2022 - cir.nii.ac.jp
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a)
reduction-DOSE finding study (OCEAN(a)-DOSE) | CiNii Research CiNii 国立情報学研究所 学術 …
reduction-DOSE finding study (OCEAN(a)-DOSE) | CiNii Research CiNii 国立情報学研究所 学術 …
[PDF][PDF] Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN (a) reduction-DOSE finding study (OCEAN (a)-DOSE)
ML O'Donoghue, JAG López, B Knusel, B Gencer… - 2022 - access.archive-ouverte.unige.ch
Archive ouverte UNIGE Study design and rationale for the Olpasiran trials of Cardiovascular
Events And lipoproteiN(a) reduction- Page 1 Archive ouverte UNIGE https://archive-ouverte.unige.ch …
Events And lipoproteiN(a) reduction- Page 1 Archive ouverte UNIGE https://archive-ouverte.unige.ch …